Dr Nghiem speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about the latest finding in the field of Merkel cell carcinoma. He highlights that there have been major developments in the settings of first-line treatment, treatment after chemotherapy and the neoadjuvant setting.
He goes on to discuss the importance and benefit of immune therapy over chemotherapy in this setting.